menu search

CMPI / Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities. The Checkmate Pharmaceuticals Analyst: Jason Zemansky upgraded Checkmate Pharmaceuticals from Neutral to Buy and lowered the price target from $19 to $7. Read More
Posted: Oct 6 2021, 15:27
Author Name: Benzinga
Views: 110695

CMPI News  

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

By Benzinga
October 6, 2021

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its o more_horizontal

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

By Benzinga
October 6, 2021

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its o more_horizontal

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

By Benzinga
October 6, 2021

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its o more_horizontal


Search within

Pages Search Results: